Full-Time

GMP Sr Manager Facilities Compliance

Posted on 8/12/2025

Evotec

Evotec

1,001-5,000 employees

Global drug-discovery services via partnerships

No salary listed

Toulouse, France

In Person

Category
Data & Analytics (4)
, , ,
Requirements
  • Master’s degree in Facilities Management, Facilities Engineering or related qualification
  • 7+ years of experience in a GMP environment with demonstrated competency in the principles and practice of cGMPs and associated regulatory considerations in a biologic manufacturing environment, including process, equipment and facility validation experience
Responsibilities
  • Have overall responsibility for the operating and monitoring program for production areas and GMP critical utilities including water for injectable (WFI), pure steam, GMP process gases, all GMP activities (cleaning,...) and the environmental control program (pest control,...)
  • Guarantee traceability of the life cycle of each piece of equipment, from its creation (SAT, SOP to be set up, etc.) to its maintenance, and its destruction in the system if obsolete.
  • Ensure GMP compliance in the Facilities & Engineering department.
  • Monitor and lead investigations into plant and equipment deviations and system failures and be responsible for implementing corrective/preventive actions (CAPA) and change controls for GMP systems.
  • Monitor all compliance action plans (non-conformities, continuous improvement, etc.) involving the team, and hold follow-up meetings.
  • Monitor maintenance and metrology programs and ensure that scheduled activities are carried out on time and documented.
  • Train, document, audit and regularly inspect our suppliers for GMP activities (carry out contradictory inspections of our service providers) and draw up GMP referencing plans for our service providers.
  • Validate documents relating to new equipment: specifications, functional analysis, SAT, reports, etc. and manage the traceability of DOEs.
  • Establish and monitor key performance indicators (to be defined with the manager) and participate in daily meetings.
  • Carry out, monitor and ensure compliance with written procedures relating to safety requirements, cGMP practices, standard operating procedures, and ensure traceability of operations (implementation of SOPs, follow-up sheets, paper or electronic logbook, job plan, etc.).
  • Guarantee technical documentation for static SATs and participation in IQs.
  • Participate in the definition of GMP requirements during work.
  • Participate to the audits (regulatories
  • Update and monitor the department's GMP documents in the electronic document management system (GED: Compliance Quest) and monitor updates to documents relating to the ANSM technical note.
  • Ensure that information relating to GMP data (QBMS) is fed into the GTC/GTB system.
  • Responsible for managing periodic checks and compliance of all equipment on the site: set up periodic inspection contracts, monitor planning, draw up and monitor the budget, traceability in the CMMS, carry out compliance monitoring, planify
  • Non-exhaustive list:
  • Electrical installations (thermography, cabinet inspection, etc.)
  • Pressure equipment
  • Mechanical and lifting equipment.
  • Fire safety systems
  • Energy and fluid networks
  • Control of hydraulic networks
  • Reinforce the Facilities & Engineering department according to the needs of the department and to be validated by the manager
Desired Qualifications
  • Experience with change control and validation related to GMP utilities and equipment
  • Practical knowledge of eQMS and CMMS
  • Working knowledge of utilities and mechanical systems
  • Working knowledge of procurement and contracts
  • Knowledge of health, safety and environmental regulations
  • Experience in maintenance and all facets of facility operation
  • Excellent verbal and written communication skills
  • Possess planning, organizational, problem-solving and negotiation skills
  • Strong focus on quality and attention to detail
  • Knowledge in regulatories activitiy
  • Motivated, self-starter with customer service and team orientation

Evotec provides R&D services for drug discovery and development through strategic partnerships with pharma, biotech, and academic institutions, using platforms like iPSCs and machine learning. It conducts experiments and data analysis with iPSC-derived cellular models and AI/ML tools to identify and optimize drug candidates, often incorporating patient-derived materials for precision medicine, offering end-to-end discovery through clinical development under contract. The company differentiates itself with an integrated, data-driven, cell-based platform within a collaboration model and a focus on precision medicine, biologics, and gene therapy, with a strong US and European presence. Its goal is to bring new and better medicines to patients faster and at lower cost by making drug discovery and development more efficient through partnerships.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hamburg, Germany

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Rui Wang strengthens AI commercialization across discovery and development.
  • J.Train could win biologics customers needing faster, smaller-footprint manufacturing.
  • Horizon restructuring targets €75 million run-rate savings by 2027.

What critics are saying

  • Q1 2026 revenue fell 21.7%, showing persistent discovery demand weakness.
  • Horizon execution requires site exits, provisions, and delayed savings delivery.
  • Leadership turnover and shareholder pressure signal governance instability during transformation.

What makes Evotec unique

  • Evotec combines drug discovery, biologics, and AI-enabled R&D platforms.
  • Just-Evotec Biologics adds continuous manufacturing and CDMO capabilities.
  • The company works with 20 top pharma and 800 biotechs.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Evotec who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Unlimited Paid Time Off

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 8th, 2026
Evotec delivers $67M cost savings and $650M Sandoz deal amid 1.1% revenue decline

Evotec SE reported mixed Q4 2025 results, with group revenue increasing 14.5% to €253.3 million, though full-year revenue fell 1.1% to €788.4 million. Adjusted group EBITDA for Q4 rose 103.6% to €58 million, whilst full-year EBITDA increased 81.9% to €41.1 million. The Just-Evotec Biologics segment achieved breakthrough growth, with Q4 revenue surging 104.2% and full-year revenue rising 39.8% to €259.4 million. The company secured a $650 million agreement with Sandoz and received multiple milestone payments from partnerships. Evotec delivered over €60 million in annualised cost savings and reduced capital expenditure by approximately 60%. The company is implementing its Horizon transformation programme, expected to deliver €75 million in structural savings by end-2027, though this involves closing four sites and eliminating 800 positions.

The Associated Press
Apr 7th, 2026
Evotec nominates Dieter Weinand as supervisory board chairman to drive commercial execution

Evotec has nominated Dieter Weinand as chairman of its supervisory board, pending approval at the 11 June 2026 annual general meeting. Weinand will succeed Prof. Dr Iris Löw-Friedrich, whose term concludes at the meeting as part of the company's planned succession process. Weinand brings over 30 years of pharmaceutical industry experience, having served as president, CEO and chairman of Bayer Pharmaceuticals and held senior roles at Pfizer, Bristol Myers Squibb and Sanofi. He currently serves on several biotech boards and will reduce his board commitments to comply with German corporate governance requirements. The appointment aims to strengthen Evotec's commercial execution, strategic partnerships and profitability as the Hamburg-based life sciences company continues its transformation. Weinand holds an MS in pharmacology and toxicology from Long Island University.

The Associated Press
Apr 1st, 2026
Evotec appoints Dr. Ashiq H. Khan as chief commercial officer with $7B+ deal track record

Evotec has appointed Dr Ashiq H Khan as chief commercial officer. Dr Khan brings over 15 years of international leadership experience in biotech, CRO and AI-driven platform businesses, having closed more than $7 billion in agreements across US, EU and APAC markets. In his new role, Dr Khan will build a globally integrated commercial organisation aligned with Evotec's scientific capabilities. He most recently served as chief business officer at Iktos and previously held leadership roles at Proteros and Schrödinger. Evotec is a life science company specialising in drug discovery and development, integrating AI-driven innovation with advanced technologies. The company employs over 4,800 experts across Europe and the US.

The Associated Press
Mar 19th, 2026
Evotec receives $10M milestone from Bristol Myers Squibb for kidney cancer drug trial

Evotec has received a $10 million milestone payment from Bristol Myers Squibb following the initiation of a Phase 1 clinical study for BMS-986506, a protein degradation treatment for advanced clear cell renal cell carcinoma, the most common form of kidney cancer. The study marks the first clinical milestone in the strategic protein degradation partnership between Evotec and Bristol Myers Squibb, which began in 2018 and was expanded in 2022. BMS-986506 is a cereblon E3 ligase modulator, or "molecular glue", developed using Evotec's multi-omics screening platform and AI-supported data analytics. The collaboration combines Evotec's PanOmics and PanHunter platforms with Bristol Myers Squibb's library of CELMoD agents to discover novel molecular glue degraders for oncology and other therapeutic areas.

Yahoo Finance
Mar 16th, 2026
Evotec unveils "Horizon" plan with $85M savings, 800 job cuts and 10-site footprint by 2028

Evotec has unveiled "Horizon", a transformation plan targeting €75 million in savings and guiding 2026 EBITDA to €0–40 million. The plan focuses on operational excellence, scientific leadership and commercial execution, building on earlier restructuring that delivered over €60 million in savings through end-2025. The company will reduce its global footprint from 14 sites to 10 over two years, resulting in approximately 800 position reductions. Evotec emphasises owned technology hubs in Toulouse and Verona as integrated discovery and preclinical development centres. Chief executive Christian Wojczewski said Evotec has upgraded commercial leadership and business development, with prospects increasing during the second half of 2025. The company previously streamlined its asset pipeline by 30% and reduced capital expenditure by 60% whilst strengthening its balance sheet.

INACTIVE